Shanthas Pentavalent Pediatric Vaccine Prequalified by World Health Organization
![](/46/pdcnewsitem/03/33/03/Fi6PvjoXFjDSRWU.png)
Sanofi Pasteur, the vaccines division of Sanofi has announced that its pediatric pentavalent vaccine Shan5, developed and manufactured by its affiliate Shantha Biotechnics in Hyderabad, has received prequalification status from the World Health Organization (WHO).
This status qualifies Shan5 vaccine for purchase by United Nations agencies, mainly UNICEF. Shan5 prequalification will give more children around the world access to the latest high-quality, fully-liquid, 5-in-1 vaccine and help secure the supply of pentavalent combination vaccines in more than 50 emerging and low-income countries.
“Shan5 is the first product that puts together the best of Shantha and Sanofi Pasteur’s assets and talents,” said Olivier Charmeil, Sanofi Pasteur President and CEO. “Today, a significant number of babies born every year do not have access to modern vaccination programmes. By delivering large supplies of high-quality and affordable vaccines to emerging and low-income countries, Shantha will be contributing to filing this gap for the benefits of babies and their parents.”
Shan5 is produced at Shantha’s state-of-the-art manufacturing facility in Hyderabad, and received Marketing Authorization in India in March 2014.
“The development of Shan5 benefitted from Sanofi Pasteur’s more than 50 years of experience with whole-cell pertussis and combination vaccines — ensuring robust processes and guaranteeing international quality standards” said Harish Iyer, Shantha CEO at a media briefing in Hyderabad. “Shantha’s manufacturing platform in India will serve Indian needs and provide Sanofi Pasteur access to additional vaccine markets globally.”
Dr Varaprasad Reddy, Founder of Shantha Biotechnics and Non-Executive Chairman of the board shared: “It is a very happy and momentous day for all of us at Shantha. My waiting period of 4 years has ended and we are very jubilant. I want to immensely thank all the scientists of Sanofi Pasteur and Shantha Biotechnics for their collective and cooperative work together, for achieving this goal of establishing Shan5. We move forward, committed and focused to our priority and passion which is to serve people through high quality, affordable vaccines.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance